Skip to content
stoqly
en Β· USD

Appearance

Language

Currency

Popular

All currencies

Data is in US dollars, converted at the ECB reference rate of Oct 26, 2026.

Sign in

Oscar Health

OSCR NYSE Managed Health Care Financials FY2019–FY2025

Oscar Health sells health insurance plans to individuals and families in the United States, mostly through the marketplaces set up under the Affordable Care Act (ACA). Employees whose employers offer an ICHRA, an arrangement in which the employer pays a set amount toward individual coverage, can also buy its plans. At the end of 2025 Oscar had about 2.0 million members. It offered coverage in 18 states in 2025 and has expanded to 20 states for 2026. Florida, Texas and Georgia have the most members.

Add to portfolio Download report

Last close Β· Oct 26, 2026

$31.10

0.4%
Value it Compare

What Oscar Health does

OSCR Β· Managed Health Care

From its latest annual report

Oscar Health sells health insurance plans to individuals and families in the United States, mostly through the marketplaces set up under the Affordable Care Act (ACA). Employees whose employers offer an ICHRA, an arrangement in which the employer pays a set amount toward individual coverage, can also buy its plans. At the end of 2025 Oscar had about 2.0 million members. It offered coverage in 18 states in 2025 and has expanded to 20 states for 2026. Florida, Texas and Georgia have the most members.

Nearly all of its revenue comes from premiums. In 2025, 93% of premiums came directly from the Centers for Medicare & Medicaid Services (CMS), through federal premium tax credits, and 7% from members. Through +Oscar it also sells its technology to other insurers and to health care providers; its Campaign Builder tool, which helps them reach patients, covered nearly 0.6 million client lives at the end of 2025. Businesses it bought in 2025 add an insurance brokerage, an enrollment platform and a consumer education website. Oscar says its main rivals are national and regional insurers, Medicaid-focused insurers and local Blue Cross plans.

Oscar had about 2,305 employees at the end of 2025. Its plans use selected networks of doctors and hospitals rather than every provider in an area, and it runs on software it built itself for claims, billing and member service. Most of its members come to it through insurance brokers.

Filing details

Legal name
Oscar Health, Inc.
Fiscal year ends
December 31, 2025
Latest annual report
10-K Β· Feb 13, 2026
Accession Β· CIK
0001568651-26-000011 Β· 0001568651
Biggest risks, in its own words

Earnings calendar Β· Oscar Health

Every quarter, companies publish how much they sold and earned. These are the days Oscar Health did it, and the next one. Share prices often move a lot on those days.

Next results

November 5, 2026

Thursday Β· in 10 days

Time
Before the market opens
Covers
Period ended Sep 30, 2026
Expected EPS
βˆ’$0.11
Source
Earnings calendar
See who else reports that week β†’
Date Results for Time Source
Aug 6, 2026 Q2 '26 Before the market opens 8-K β†—
May 6, 2026 Q1 '26 Before the market opens 8-K β†—
Feb 6, 2026 Q4 '25 Time not announced 8-K β†—
Nov 3, 2025 Q3 '25 Time not announced 8-K β†—
Jul 22, 2025 Q2 '25 Before the market opens 8-K β†—
May 7, 2025 Q1 '25 Before the market opens 8-K β†—
Jan 29, 2025 Q4 '24 Time not announced 8-K β†—
Nov 7, 2024 Q3 '24 Before the market opens 8-K β†—

From SEC filings: the results press release (8-K) or, without one, the quarterly or annual report.

KIRA’s summary AI analyst

Hi! I read Oscar Health’s latest annual report (fiscal 2025). Here is what stands out:

3 strengths 2 to watch

1.Sales and profit

See section β†’
  • Oscar Health had $11.7B of revenue in fiscal 2025, up 27.5% on the year before. Over five years, revenue changed +90.8% a year on average.
  • Its operating margin was βˆ’3.4%, down 4.0Β pts: of every 100 in sales, about βˆ’3 is left after running the business.
  • Oscar Health lost $443M in fiscal 2025.

2.Cash and shareholders

See section β†’
  • Free cash flow was $1.1B in fiscal 2025, 9.1% of revenue.
  • Oscar Health returned $0.0M to shareholders in fiscal 2025, 0% of free cash flow. The diluted share count fell 1.3%.
  • In the last 12 months, insiders bought $11.9M and sold $150M of shares on the open market.

4.Price and value

See section β†’
  • At $31.10 a share, the company is worth $10.4B: 23.9 times its earnings of the last four quarters.
  • Oscar Health grew sales faster than 4 of its 4 similar companies. Its P/E is higher than 0 of 2.

Biggest risks, in its own words

  • Failing to add or keep members, especially as new federal rules and laws reshape the ACA marketplaces where it sells its plans.
  • Misjudging medical costs or how sick its members are, which could leave premiums too low to cover claims.
  • Risk adjustment programs, which move money between insurers based on members' health, can cut the revenue it records.
  • Its concentration in a few states, and its reliance on a limited number of in-network doctors and hospitals.
  • Its history of losses, and the chance that it does not reach or keep profitability.

Oscar Health in 30 seconds

Good So-so Weak

Good

Are sales growing?

+27.5%

Yes. Sales grew 27.5% last year.

Weak

Does it make a profit?

βˆ’3.8%

No. It lost money last year.

So-so

Does profit turn into cash?

9.1%

Partly. 9.1% of sales ends up as free cash.

So-so

How healthy are the accounts?

4 / 8

Mixed. It passes 4 of 8 health tests.

For information

How is the share priced?

23.9x

One share costs 23.9 times its yearly profit per share. Typical for its sector: 28.4x.

Rules of thumb on reported numbers. A starting point, not a recommendation.

Key numbers, fiscal 2025

Market cap Last close times the latest diluted share count, so it is approximate.
$10.4B
Oct 26 close
P/E Last close divided by diluted earnings per share over the last four quarters.
23.9x
On $1.30 EPS (TTM)

Revenue

Total sales reported in the income statement.

KIRA Β· Oscar Health had $11.7B of revenue in fiscal 2025, up 27.5% on the year before. Over five years, revenue changed +90.8% a year on average.

See the full section β†’

Operating margin

Operating income as a share of revenue.

KIRA Β· Its operating margin was βˆ’3.4%, down 4.0Β pts: of every 100 in sales, about βˆ’3 is left after running the business.

See the full section β†’

Net income

Profit after all expenses, interest and tax.

KIRA Β· Oscar Health lost $443M in fiscal 2025.

See the full section β†’

Free cash flow

Cash from operations minus capital spending.

KIRA Β· Free cash flow was $1.1B in fiscal 2025, 9.1% of revenue.

See the full section β†’

Return on capital

After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.

See the full section β†’

About these figures. Oscar Health's EBITDA was negative in 2023 and 2025, so net debt to EBITDA is left blank in those years.

Charts by

Sales and profit

Is it selling more, and how much does it keep?

Revenue and margins

KIRA Β· Oscar Health had $11.7B of revenue in fiscal 2025, up 27.5% on the year before. Over five years, revenue changed +90.8% a year on average. Its operating margin was βˆ’3.4%, down 4.0Β pts: of every 100 in sales, about βˆ’3 is left after running the business.

In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).

Revenue

Revenue

Margins, % of revenue

Gross Operating Net FCF

Margins, % of revenue

Gross Operating Net FCF

Net income and earnings per share

KIRA Β· Oscar Health lost $443M in fiscal 2025.

Loss periods are shown in red.

In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.

Net income

Net income

Diluted EPS

Diluted EPS

Cash and shareholders

How much cash comes in, and where does it go?

Cash flow

KIRA Β· Free cash flow was $1.1B in fiscal 2025, 9.1% of revenue.

Cash from operations minus capital spending.

In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.

Free cash flow

Free cash flow

Cash from operations vs capital spending

Cash from operations Capital spending

Cash from operations vs capital spending

Cash from operations Capital spending

Dividends, buybacks and share count

KIRA Β· Oscar Health returned $0.0M to shareholders in fiscal 2025, 0% of free cash flow. The diluted share count fell 1.3%.

In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).

Dividends and buybacks

Dividends Buybacks

Dividends and buybacks

Dividends Buybacks

Diluted shares outstanding (annual)

Insider trades

KIRA Β· In the last 12 months, insiders bought $11.9M and sold $150M of shares on the open market.

Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. β€œPlan” marks trades under a pre-arranged Rule 10b5-1 plan.

In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.

Bought, 12 months

$11.9M

1 insider

Sold, 12 months

$150M

7 insiders

Of sales under plans

80%

$121M

DateInsiderTradeSharesPriceValueFiling
Sep 18, 2026 Vanessa Ames WittmanDirector Sold plan 25,000 $32.24 $0.8M Form 4
Sep 3, 2026 Victoria BaltrusChief Accounting Officer Sold plan 958 $31.45 $0.0M Form 4
Sep 3, 2026 Adam McAnaneyChief Legal Officer Sold plan 9,092 $31.45 $0.3M Form 4
Sep 3, 2026 Richard Scott BlackleyChief Financial Officer Sold plan 28,869 $31.45 $0.9M Form 4
Sep 3, 2026 Mario SchlosserDirector Sold plan 31,422 $31.45 $1.0M Form 4
Sep 3, 2026 Janet LiangPresident, Oscar Insurance Sold plan 10,360 $31.45 $0.3M Form 4
Aug 28, 2026 Mario SchlosserDirector Sold 150,000 $30.79 $4.6M Form 4
Aug 27, 2026 Mario SchlosserDirector Sold 600,000 $30.34 $18.2M Form 4
Aug 18, 2026 Richard Scott BlackleyChief Financial Officer Sold 18,750 $31.74 $0.6M Form 4
Jul 1, 2026 Mario SchlosserDirector Sold plan 47,500 $31.24 $1.5M Form 4
Jun 30, 2026 Mark T BertoliniChief Executive Officer, Director Sold plan 624,244 $28.48 $17.8M Form 4
Jun 29, 2026 Mark T BertoliniChief Executive Officer, Director Sold plan 614,752 $29.26 $18.0M Form 4
Jun 26, 2026 Mark T BertoliniChief Executive Officer, Director Sold plan 591,168 $29.28 $17.3M Form 4
Jun 25, 2026 Mark T BertoliniChief Executive Officer, Director Sold plan 615,142 $28.61 $17.6M Form 4
Jun 23, 2026 Mario SchlosserDirector Sold plan 1,027,398 $29.38 $30.2M Form 4
Jun 2, 2026 Mario SchlosserDirector Sold plan 34,120 $21.94 $0.7M Form 4
Jun 2, 2026 Janet LiangPresident, Oscar Insurance Sold plan 12,475 $21.94 $0.3M Form 4
Jun 2, 2026 Richard Scott BlackleyChief Financial Officer Sold plan 31,683 $21.94 $0.7M Form 4
Jun 2, 2026 Adam McAnaneyChief Legal Officer Sold plan 9,859 $21.94 $0.2M Form 4
Jun 2, 2026 Victoria BaltrusChief Accounting Officer Sold plan 1,523 $21.94 $0.0M Form 4
May 18, 2026 Richard Scott BlackleyChief Financial Officer Sold plan 110,000 $25.03 $2.8M Form 4
May 14, 2026 Richard Scott BlackleyChief Financial Officer Sold plan 100,000 $23.16 $2.3M Form 4
Apr 6, 2026 Mark T BertoliniChief Executive Officer, Director Bought 1,000,000 $11.92 $11.9M Form 4
Mar 2, 2026 Adam McAnaneyChief Legal Officer Sold plan 18,710 $13.39 $0.3M Form 4
Mar 2, 2026 Richard Scott BlackleyChief Financial Officer Sold plan 19,221 $13.39 $0.3M Form 4
Mar 2, 2026 Victoria BaltrusChief Accounting Officer Sold plan 4,638 $13.39 $0.1M Form 4
Mar 2, 2026 Janet LiangPresident, Oscar Insurance Sold plan 7,453 $13.39 $0.1M Form 4
Mar 2, 2026 Mario SchlosserPresident of Technology & CTO, Director Sold plan 24,335 $13.39 $0.3M Form 4
Jan 8, 2026 Mario SchlosserPresident of Technology & CTO, Director Sold plan 23,038 $17.65 $0.4M Form 4
Jan 6, 2026 Mario SchlosserPresident of Technology & CTO, Director Sold plan 76,962 $17.01 $1.3M Form 4
Jan 5, 2026 Mario SchlosserPresident of Technology & CTO, Director Sold plan 96,928 $15.64 $1.5M Form 4
Jan 2, 2026 Mario SchlosserPresident of Technology & CTO, Director Sold plan 137,933 $15.02 $2.1M Form 4
Dec 24, 2025 Mario SchlosserPresident of Technology & CTO, Director Sold plan 38,835 $15.00 $0.6M Form 4
Dec 2, 2025 Adam McAnaneyChief Legal Officer Sold plan 1,852 $16.59 $0.0M Form 4
Dec 2, 2025 Richard Scott BlackleyChief Financial Officer Sold plan 25,135 $16.59 $0.4M Form 4
Dec 2, 2025 Janet LiangPresident, Oscar Insurance Sold plan 7,338 $16.59 $0.1M Form 4
Dec 2, 2025 Victoria BaltrusChief Accounting Officer Sold plan 4,149 $16.59 $0.1M Form 4
Dec 2, 2025 Mario SchlosserPresident of Technology & CTO, Director Sold plan 23,965 $16.59 $0.4M Form 4
Nov 12, 2025 Mario SchlosserPresident of Technology & CTO, Director Sold 105,300 $15.05 $1.6M Form 4
Nov 11, 2025 Mario SchlosserPresident of Technology & CTO, Director Sold 286,182 $15.27 $4.4M Form 4

Financial health

Can it carry its debts, and how well does it use its money?

Balance sheet

KIRA Β· Oscar Health has $3.6B more cash than debt.

Cash, debt and the ratios that show how comfortably Oscar Health can carry it.

In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.

Cash vs debt (incl. leases)

Cash Debt
Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments $1.7B$3.0B$2.6B$2.2B$4.0B
Debt incl. finance leases $0.0M$298M$299M$300M$430M
Net debt / EBITDA β€”β€”β€”βˆ’20.7xβ€”
Debt / equity 0.0x0.3x0.4x0.3x0.4x
Interest coverage βˆ’115.4xβˆ’26.1xβˆ’9.6x2.4xβˆ’22.5x
Current ratio 1.2x1.3x1.3x0.8x1.0x
Quick ratio 1.2x1.3x1.3x0.8x1.0x
Total assets $3.3B$4.5B$3.6B$4.8B$6.3B
Total liabilities $1.9B$3.6B$2.8B$3.8B$5.3B
Shareholders' equity $1.4B$890M$804M$1.0B$978M
Net debt (βˆ’ = net cash) βˆ’$1.7Bβˆ’$2.7Bβˆ’$2.3Bβˆ’$1.9Bβˆ’$3.6B

Returns on capital

After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.

In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.

Return on capital, equity and assets (annual)

Return on capital Return on equity Return on assets

Piotroski F-score

KIRA Β· Oscar Health passes 4 of 8 financial health tests (Piotroski F-score).

Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.

In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.

TestFY23FY24FY25
Net income is positive βœ• βœ“ βœ•
Cash from operations is positive βœ• βœ“ βœ“
Return on assets rose βœ“ βœ“ βœ•
Cash from operations exceeds net income βœ• βœ“ βœ“
Debt fell relative to assets βœ“ βœ“ βœ•
Current ratio rose βœ• βœ• βœ“
Share count didn't rise βœ• βœ• βœ“
Gross margin rose β€” β€” β€”
Revenue rose relative to assets βœ“ βœ“ βœ•
F-score 3 / 86 / 84 / 8
Accruals ratio 0.0%βˆ’22.6%βˆ’27.6%
Altman Z'' βˆ’1.59βˆ’2.40βˆ’2.18

Price and value

What does the share cost, and how does it compare?

Value Oscar Health yourself

KIRA Β· At $31.10 a share, the company is worth $10.4B: 23.9 times its earnings of the last four quarters.

Change the assumptions and see what they imply per share. These are models, not forecasts or price targets β€” the answer depends entirely on what you put in.

In plain words: Move the sliders to try your own guesses about growth. The result is what one share would be worth if those guesses came true. Different guesses give very different answers.

Discounted cash flow

Value per share

β€”

Adds net cash of $3.6B and divides by 262.4M diluted shares. Ten years of cash flows plus a terminal value, discounted to today.

Earnings multiple

Value per share

β€”

Reference multiples: today 23.8x Β· peers 41.3x Β· sector 28.4x.

Similar companies

KIRA Β· Oscar Health grew sales faster than 4 of its 4 similar companies. Its P/E is higher than 0 of 2.

Each company’s latest fiscal year. Fiscal years end in different months, so periods don’t line up exactly.

In plain words: The same numbers for similar companies, so you can tell whether a figure is high or low for this kind of business.

CompanyMarket capGrowthOp. marginFCF marginROICP/EF-score
Oscar Health OSCR $10.4B 27.5% βˆ’3.4% 9.1% β€” 23.9x 4
Molina Healthcare MOH $10.5B 11.8% 1.7% βˆ’1.4% β€” β€” 4 Compare β†’
HealthEquity HQY $8.7B 9.5% 24.6% 34.7% 8.9% 37.5x 9 Compare β†’
Humana HUM $50.4B 10.1% 2.1% 0.3% 25.7% 44.5x 5 Compare β†’
Centene CNC $33.9B 19.4% βˆ’3.9% 2.2% βˆ’26.4% β€” 5 Compare β†’

All figures

Every number, year by year.

7 years of figures

Amounts in USD. Hover a ratio’s name for its definition.

In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.

Download CSV
Fiscal yearFY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue $488M $463M $1.8B $4.0B $5.9B $9.2B $11.7B
Operating income βˆ’$259M βˆ’$402M βˆ’$545M βˆ’$590M βˆ’$236M $57.3M βˆ’$396M
Interest expense $0.0M $3.5M $4.7M $22.6M $24.6M $23.7M $17.6M
Pretax income βˆ’$259M βˆ’$406M βˆ’$571M βˆ’$610M βˆ’$267M $33.4M βˆ’$437M
Income tax $1.8M $1.0M $0.8M βˆ’$0.5M $3.3M $7.3M $5.6M
Net income βˆ’$261M βˆ’$407M βˆ’$573M βˆ’$606M βˆ’$271M $25.4M βˆ’$443M
Diluted EPS βˆ’$9.06 βˆ’$14.16 βˆ’$3.20 βˆ’$2.85 βˆ’$1.22 $0.10 βˆ’$1.69
Diluted shares 0.03B 0.03B 0.18B 0.21B 0.22B 0.27B 0.26B
Cash flow
Cash from operations βˆ’$165M $223M βˆ’$182M $380M βˆ’$272M $978M $1.1B
Capital expenditure $26.0M $14.0M $25.9M $29.0M $25.6M $27.9M $36.4M
Free cash flow βˆ’$191M $209M βˆ’$208M $351M βˆ’$298M $950M $1.1B
Depreciation and amortization $6.9M $11.3M $14.6M $15.3M $30.7M $32.1M $28.9M
Stock-based compensation $33.6M $35.9M $86.3M $112M $160M $110M $87.7M
Acquisitions $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M
Share buybacks $3.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M
Dividends paid $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M
Dividends and buybacks $3.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M
Balance sheet
Cash and short-term investments $337M $1.2B $1.7B $3.0B $2.6B $2.2B $4.0B
Total debt β€” $143M $0.0M $298M $299M $300M $430M
Finance lease liabilities $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M
Current assets β€” $1.9B $2.3B $4.1B $3.1B $2.8B $4.6B
Current liabilities β€” $1.7B $1.9B $3.3B $2.4B $3.5B $4.9B
Inventory $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M
Property and equipment, net β€” $35.8M $46.6M $59.9M $61.9M $66.8M $88.3M
Total assets β€” $2.3B $3.3B $4.5B $3.6B $4.8B $6.3B
Total liabilities β€” $1.8B $1.9B $3.6B $2.8B $3.8B $5.3B
Shareholders' equity $0.0M βˆ’$1.3B $1.4B $890M $804M $1.0B $978M
Margins
Operating margin βˆ’53.1% βˆ’86.9% βˆ’29.6% βˆ’14.9% βˆ’4.0% 0.6% βˆ’3.4%
EBITDA margin βˆ’51.7% βˆ’84.5% βˆ’28.8% βˆ’14.5% βˆ’3.5% 1.0% βˆ’3.1%
Net margin βˆ’53.5% βˆ’87.9% βˆ’31.1% βˆ’15.3% βˆ’4.6% 0.3% βˆ’3.8%
FCF margin βˆ’39.2% 45.1% βˆ’11.3% 8.9% βˆ’5.1% 10.4% 9.1%
Returns
Return on capital employed β€” β€” βˆ’52.5% βˆ’43.2% βˆ’19.4% 4.5% βˆ’27.9%
Return on equity β€” β€” β€” βˆ’53.2% βˆ’32.0% 2.8% βˆ’44.5%
Return on assets β€” β€” βˆ’20.5% βˆ’15.5% βˆ’6.7% 0.6% βˆ’7.9%
Growth
Revenue growth β€” βˆ’5.2% 297.3% 115.6% 47.9% 56.5% 27.5%
Net income growth β€” β€” β€” β€” β€” β€” βˆ’1,842.5%
EPS growth β€” β€” β€” β€” β€” β€” βˆ’1,790.0%
FCF growth β€” β€” βˆ’199.5% β€” βˆ’184.7% β€” 11.4%
Share count change β€” 1.6% 511.6% 18.7% 4.3% 19.9% βˆ’1.3%
Financial health
Net debt / EBITDA β€” β€” β€” β€” β€” βˆ’20.7x β€”
Debt / equity β€” β€” 0.0x 0.3x 0.4x 0.3x 0.4x
Interest coverage β€” βˆ’114.5x βˆ’115.4x βˆ’26.1x βˆ’9.6x 2.4x βˆ’22.5x
Current ratio β€” 1.1x 1.2x 1.3x 1.3x 0.8x 1.0x
Quick ratio β€” 1.1x 1.2x 1.3x 1.3x 0.8x 1.0x
Capital allocation
Capex / revenue 5.3% 3.0% 1.4% 0.7% 0.4% 0.3% 0.3%
Stock comp / revenue 6.9% 7.8% 4.7% 2.8% 2.7% 1.2% 0.8%
Payouts / FCF β€” 0.0% β€” 0.0% β€” 0.0% 0.0%
Quality scores
Piotroski F-score β€” β€” β€” 5.0 3.0 6.0 4.0
Altman Z'' β€” βˆ’3.4 βˆ’1.4 βˆ’1.3 βˆ’1.6 βˆ’2.4 βˆ’2.2
Accruals ratio β€” β€” βˆ’14.0% βˆ’25.1% 0.0% βˆ’22.6% βˆ’27.6%

Source: SEC EDGAR XBRL filings (CIK 0001568651). Data updated October 11, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β€” not investment advice. Check the original filings before relying on any figure.

↑ ↓ to move Β· ↡ to open